Skip to main navigation Skip to search Skip to main content

EGFR as a predictor of relapse in myxopapillary ependymoma

  • Anupam Verma
  • , Holly Zhou
  • , Steve Chin
  • , Carol Bruggers
  • , John Kestle
  • , Soumen Khatua

Research output: Contribution to journal › Article › peer-review

Abstract

Myxopapillary ependymoma (MPE) is a rare subtype of ependymoma in children. Though classified as a Grade I tumor, their unpredictable behavior and propensity for local and disseminated recurrence poses a therapeutic challenge. Till date no predictive molecular markers exist for such recurrence, especially with dissemination. We demonstrated that Epidermal Growth Factor Receptor (EGFR) expression was seen in relapsed MPE both at diagnosis and at recurrence and none in the nonrecurring tumors. This finding suggests EGFR could be a predictive biomarker for recurrence in MPE. Pediatr Blood Cancer 2012;59:746-748.

Original languageEnglish (US)
Pages (from-to)746-748
Number of pages3
JournalPediatric Blood and Cancer
Volume59
Issue number4
DOIs
StatePublished - Oct 2012

Keywords

  • EGFR
  • Myxopapillary ependymoma
  • Prognostic marker
  • Recurrence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'EGFR as a predictor of relapse in myxopapillary ependymoma'. Together they form a unique fingerprint.

Cite this